rs1800471 — TGFB1 R25P (Arg25Pro)

TGF-β1 R25P — When the Body's Scar-Maker Works Overtime

Transforming growth factor beta 1 (TGF-β1) is one of the most versatile signaling molecules in the cardiovascular system — it can stabilize arterial plaques, suppress excessive inflammation, and regulate the repair of damaged heart muscle. But when TGF-β1 production tips too high or its signaling becomes dysregulated, the same molecule drives fibrosis, atherosclerosis progression, and myocardial remodeling after injury. The rs1800471 variant (R25P, Arg25Pro) sits in the signal peptide of the TGFB1 gene on chromosome 19q13¹¹ chromosome 19q13
NC_000019.10:g.41352971C>G; TGFB1 encodes the inactive pre-pro-protein, cleaved to the active dimer, altering how efficiently the protein is threaded into the endoplasmic reticulum and ultimately secreted. The minor G allele (Pro25 on plus strand, coding C at position 915) influences TGF-β1 levels and has been linked to cardiovascular outcomes in multiple cohorts — though the direction and magnitude of risk are modest and population-dependent.

The Mechanism

The signal peptide is the N-terminal zip code that directs newly synthesized proteins into the secretory pathway. The Arg25Pro substitution changes a positively charged arginine to a neutral proline²² changes a positively charged arginine to a neutral proline
Proline introduces a rigid kink in the peptide backbone, potentially disrupting signal-peptide secondary structure and slowing translocation in this critical region. Functional studies show that different haplotypes formed by the codon 10 (rs1800470, L10P) and codon 25 (rs1800471, R25P) variants stratify individuals into high, intermediate, and low TGF-β1 producers³³ high, intermediate, and low TGF-β1 producers
Leukocyte in-vitro assays measuring TGF-β1 in cell supernatants after stimulation classify genotype combinations into production categories. The GG coding genotype (homozygous Arg25, corresponding to plus-strand CC) is most commonly associated with highest TGF-β1 secretion capacity; the heterozygous state produces intermediate levels.

TGF-β1 has a dual and context-dependent role in the vasculature. At physiological levels it stabilizes atherosclerotic plaques⁴⁴ stabilizes atherosclerotic plaques
TGF-β1 promotes smooth muscle cell contractility and fibrous cap formation, reducing plaque vulnerability to rupture and suppresses macrophage-mediated inflammation. At chronically elevated levels, it drives myocardial and vascular fibrosis⁵⁵ drives myocardial and vascular fibrosis
Activates cardiac fibroblasts, increases collagen deposition, promotes atrial and ventricular remodeling — contributing to arrhythmia susceptibility, reduced cardiac compliance, and post-MI scarring.

The Evidence

The most comprehensive genetic evidence comes from a 2012 meta-analysis of 5 studies⁶⁶ 2012 meta-analysis of 5 studies
Qu et al., BMC Medical Genetics, 14,452 participants total that found minor allele (coding C, plus-strand G) carriers had a pooled OR of 1.16 (95% CI 1.02–1.32) for coronary heart disease. The heterozygous GC (coding, plus-strand CG) genotype conferred OR 1.15 (1.01–1.31) versus homozygous major allele carriers. However, statistical significance disappeared after Egger's test correction for publication bias, highlighting the modest and population-heterogeneous nature of the association.

Orthogonal evidence from fibrotic and electrophysiological studies is more consistent. A study of essential hypertensive patients⁷⁷ study of essential hypertensive patients
Chen et al., Journal of Biomedical Science 2010, n=259 found the GG coding genotype was significantly overrepresented in patients with both hypertension and atrial fibrillation versus hypertension alone (P=0.009). GG coding carriers had the highest serum TGF-β1 levels among AF-positive subjects, with a 3.09-fold elevated AF risk in this context. Since atrial fibrosis is the primary substrate for atrial fibrillation, this provides a mechanistic link from the genotype through TGF-β1 to cardiac remodeling.

A Russian cohort study of MI patients⁸⁸ Russian cohort study of MI patients
Contribution of TGFB1 to MI susceptibility, PMC3408705 found the GG coding genotype (high producer) significantly enriched in MI cases versus controls (OR 1.76, 95% CI 1.05–2.97, P=0.048). A study of TGFB1 and coronary heart disease with angiographic confirmation⁹⁹ TGFB1 and coronary heart disease with angiographic confirmation
Lamblin et al., PMID 16543493 similarly linked codon 25 variants to MI in patients with confirmed CHD. The Rotterdam Study (n=5,972)¹⁰¹⁰ Rotterdam Study (n=5,972)
Verhoeven et al., Thrombosis and Haemostasis 2006 found no association with MI, illustrating the population-specific heterogeneity that characterizes this SNP.

Additional context: rs1800471 has been associated with hypertension and CKD progression¹¹¹¹ hypertension and CKD progression
Polish cohort, Archives of Medical Science 2013, consistent with the broader role of TGF-β1 in cardiovascular-renal fibrotic pathways.

Practical Actions

The cardiovascular implications of rs1800471 are primarily mediated through TGF-β1's effect on vascular inflammation and fibrosis. Carrying the minor G allele (plus strand) is associated with lower TGF-β1 production, and the heterozygous state shows modest CHD risk in aggregate analyses. Monitoring for early signs of cardiovascular disease and specific management of fibrosis-related risk factors (blood pressure, myocardial stiffness) are most relevant to this variant's biology.

Interactions

rs1800471 (codon 25) and rs1800470 (codon 10, L10P) are the two primary coding variants in the TGFB1 signal peptide. Together they form haplotypes that stratify TGF-β1 production capacity. The codon 10 high-producer T allele (rs1800470) and codon 25 G coding allele (rs1800471) combine into distinct HIGH, INTERMEDIATE, and LOW producer haplotypes. Carriers of both high-producer alleles across both codons show the strongest elevation in TGF-β1 secretion and likely the highest cumulative cardiovascular risk through fibrotic pathways. The rs1800469 promoter variant (-509 C/T) provides additional regulation of TGF-β1 transcription and should be interpreted alongside the coding variants.